ArticleDiabetes care2024
Assessment of Glycemic Control by Continuous Glucose Monitoring, Hemoglobin A1c, Fructosamine, and Glycated Albumin in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes.
Article in Diabetes care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05741489 (Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Continuous Glucose Monitoring in Patients With End-Stage Kidney Disease and Burnt-Out Diabetes
Who cites it
21 citing papers in PubMed, 25 citations in OpenAlex.
- Real-Time Continuous Glucose Monitoring Among People With Type 2 Diabetes and End-Stage Kidney Failure Undergoing Maintenance Hemodialysis: A Randomized Clinical Trial.Diabetes care · 2026Trial
- Comparative Evaluation of Traditional and Emerging Glycemic Biomarkers in Diabetes.Current issues in molecular biology · 2026Review
- Correlation Between Glycemic Biomarkers and Continuous Glucose Monitoring Metrics in Chronic Kidney Disease: A Systematic Review and Correlation Meta-Analysis.Journal of clinical medicine · 2026Review
- Accuracy, Variability, and Bias of Glycemic Biomarkers in Patients Treated With Maintenance Dialysis.Diabetes care · 2026Article
- Continuous glucose monitoring reveals distinct clinical implications of glucose levels at the start and end of hemodialysis in people with type 2 diabetes.BMC endocrine disorders · 2026Article
- Normal glycosylated hemoglobin masking glucose dysregulation in a patient with pancreatic and hematologic disease.JCEM case reports · 2026Article
- Glycemic assessment when hemoglobin A1c is unreliable: a clinical-laboratory framework for kidney disease, anemia, and hemoglobinopathies.Frontiers in endocrinology · 2026Review
- First Trimester Mean Glucose Level on Continuous Glucose Monitoring Is Associated with Infant Birth Weight.Diabetes & metabolism journal · 2025Observational
- Continuous Glucose Monitoring Improves Detection of Glycemic Excursions in Hemodialysis Patients With Type 2 Diabetes.The Journal of clinical endocrinology and metabolism · 2025Observational
- Scoping Review-Diabetes Technology for Individuals on Kidney Replacement Therapy (Dialysis): Current Trends and Future Directions.Journal of diabetes science and technology · 2025Review
- Article
- The Association Between Hemoglobin A1c and Complications Among Individuals With Diabetes and Severe Chronic Kidney Disease.Diabetes care · 2025Article
- Time to Plan for Continuous Glucose Monitoring in Dialysis-Dependent Kidney Failure.Journal of the American Society of Nephrology : JASN · 2025Article
- Cardiac arrhythmia and hypoglycaemia among individuals with and without diabetes receiving haemodialysis (the CADDY study): a Danish multicentre cohort study.Diabetologia · 2025Observational
- Glycemia Assessed by Continuous Glucose Monitoring among People Treated with Maintenance Dialysis.Journal of the American Society of Nephrology : JASN · 2025Article
- Glycemic Management and Individualized Diabetes Care in Dialysis-Dependent Kidney Failure.Diabetes care · 2025Review
- Diabetes and Glucose Management in People on Hemodialysis.Diabetes spectrum : a publication of the American Diabetes Association · 2025Article
- Improving kidney transplant care through the application of continuous glucose monitoring - a narrative review.Frontiers in nephrology · 2025Review
- Accuracy of Continuous Glucose Monitoring in Hemodialysis Patients With Diabetes.Diabetes care · 2024Article
- Continuous Glucose Monitoring Metrics and Hemoglobin A1c Relationship in Patients with Type 2 Diabetes Treated by Hemodialysis.Diabetes technology & therapeutics · 2024Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
objectivePatients with diabetes and end-stage kidney disease (ESKD) may experience "burnt-out diabetes," defined as having an HbA1c value <6.5% without antidiabetic therapy for >6 months. We aim to assess glycemic control by continuous glucose monitoring (Dexcom G6 CGM) metrics and glycemic markers in ESKD patients on hemodialysis with burnt-out diabetes. RESEARCH DESIGN AND
methodsIn this pilot prospective study, glycemic control was assessed by continuous glucose monitoring (CGM), HbA1c measures, and glycated albumin and fructosamine measurements in patients with burnt-out diabetes (n = 20) and without a history of diabetes (n = 20).
resultsPatients with burnt-out diabetes had higher CGM-measured daily glucose levels, lower percent time in the range 70-180 mg/dL, higher percent time above range (>250 mg/dL), and longer duration of hyperglycemia >180 mg/dL (hours/day) compared with patients without diabetes (all P < 0.01). HbA1c and fructosamine levels were similar; however, patients with burnt-out diabetes had higher levels of glycated albumin than did patients without diabetes.
conclusionsThe use of CGM demonstrated that patients with burnt-out diabetes have significant undiagnosed hyperglycemia. CGM and glycated albumin provide better assessment of glycemic control than do values of HbA1c and fructosamine in patients with ESKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.